Modest increases in mutation rates (3-4x) were observed at concentrations between 3.75-10.0 mg/mL in L5178Y cells in vitro with the addition of a metabolic activation fraction. For both pressure and volume ventilators, heated wire connective tubing and bacteria filters in series in the expiratory limb of the system (which must be changed frequently, i.e., every 4 hours) must be used to minimize the risk of Ribavirin for Inhalation Solution, USP precipitation in the system and the subsequent risk of ventilator dysfunction.
Either a pressure or volume cycle ventilator may be used in conjunction with the SPAG-2. Synonym: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide CAS Number: 36791-04-5. Ribavirin is a synthetic nucleoside with antiviral activity. However, results of a chronic feeding study with ribavirin in rats, at doses of 16-100 mg/kg/day (estimated human equivalent of 2.3-14.3 mg/kg/day, based on body surface area adjustment for the adult), suggest that ribavirin may induce benign mammary, pancreatic, pituitary and adrenal tumors. Nearly all were in individuals providing direct care to infants receiving aerosolized Ribavirin for Inhalation Solution, USP. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.Calculated molecular properties are available for small molecules and natural products (not peptides). Survival of fetuses and offspring was reduced. MDL number: MFCD00058564.
The minimum interval following exposure to Ribavirin for Inhalation Solution, USP before pregnancy may be safely initiated is unknown (see Ribavirin for Inhalation Solution, USP has been shown to be toxic to lactating animals and their offspring. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. In either case, patients should have their endotracheal tubes suctioned every 1-2 hours, and their pulmonary pressures monitored frequently (every 2-4 hours). Posology. Thus the terminal half-life for the systemic elimination of ribavirin is essentially that of the half-life of circulating erythrocytes. Also, cases of anemia (type unspecified), reticulocytosis and hemolytic anemia associated with aerosolized Ribavirin for Inhalation Solution, USP use have been reported through post-marketing reporting systems. It is used to treat menstrual disorders in women caused due to a lack of hormones. Several cases have been characterized as "possibly related" to Ribavirin for Inhalation Solution, USP by the treating physician; these were in infants who experienced worsening respiratory status related to bronchospasm while being treated with the drug. For more info on each category see the Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.Links are provided in return for sponsorship, used to fund improvements to this database. 5 Products.
It is also used to reduce the risk of miscarriages or abortions. No teratogenic effects were evident in the rabbit and rat administered daily oral doses of 0.1 and 0.3 mg/kg, respectively with estimated human equivalent doses of 0.01 and 0.04 mg/kg, based on body surface area adjustment (see Following oral administration of ribavirin in the pregnant rat (1.0 mg/kg) and rabbit (0.3 mg/kg), mean plasma levels of drug ranged from 0.10-0.20 Although clinical studies have not been performed, Ribavirin for Inhalation Solution, USP may cause fetal harm in humans. The incidence and severity of teratogenic effects increased with escalation of the drug dose. Respiratory function should be carefully monitored during treatment. Due to the teratogenic potential of ribavirin, the tablets should not be broken or crushed. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Studies of environmental exposure in treatment settings have shown that the drug can disperse into the immediate bedside area during routine patient care activities with highest ambient levels closest to the patient and extremely low levels outside of the immediate bedside area. Since the drug's approval in 1986, additional reports of similar serious, though non-fatal, events have been filed infrequently. PubChem Substance ID: 24278685.